Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00122603 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv11
  2. Enrollment target: estimated 60 to confirmed 61 Interventions: atazanavir (Drug), fosamprenavir (Drug), ritonavir (Drug), saquinavir (Drug) to Fosamprenavir (Drug), Saquinavir (Drug) · Study arms: 0 to 2v10 Show all 3 changesShow less
    • Interventions: atazanavir (Drug), fosamprenavir (Drug), ritonavir (Drug), saquinavir (Drug) to Fosamprenavir (Drug), Saquinavir (Drug)
    • Study arms: 0 to 2
  3. Study title expanded, about 1 wordv9 Show moreShow less

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Active, Not Recruiting to Completed Completion date: Aug 2007v8 Show all 2 changesShow less
    • Completion date: Aug 2007
  5. Trial status: Recruiting to Active, Not Recruiting Site details revisedv7 Show all 2 changesShow less
    • Site details revised
Show 5 earlier versionsHide 5 earlier versions
  1. Study site revisedv6 Show moreShow less

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Start date: Sep 2005 to Dec 2005 · Study site revisedv5 Show all 3 changesShow less
    • Start date: Sep 2005 to Dec 2005
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  3. 2 versions Re-verified since Jul 28, 2005, no change to tracked fieldsv3-v4
  4. Phase: Phase 3 to Phase 2 Secondary endpoints revised (3) · Study description revised · Eligibility criteria expanded, about 2 words · 1 morev2 Show all 5 changesShow less
    • Secondary endpoints revised (3)
    • Study description revised
    • Eligibility criteria expanded, about 2 words
    • Study title shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate virological efficacy and safety of two double protease inhibitor regimens: atazanavir/fosamprenavir/ritonavir 300 mg once daily/ 700/100 mg twice daily, versus atazanavir/saquinavir/ritonavir 300/1500/100 mg once daily in protease inhibitor naive HIV-1 patients.
Trial Details
NCT Number NCT00122603
Lead Sponsor French National Agency for Research on AIDS and Viral Hepatitis
Collaborators: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche
Conditions HIV Infections
Enrollment 61 participants
Start Date
Study Completion (estimated)
Updated on ClinicalTrials.gov